In a late-Saturday session at this year's annual American Diabetes Association (ADA) meeting, held 8-11 June in San Francisco, Abbott Laboratories Inc. presented retrospective real-world data suggesting that its FreeStyle Libre continuous glucose monitoring (CGM) system reduces HbA1c levels in type 2 diabetics.
HbA1c reflects a person's average blood sugar over a period of three months and is considered the gold standard to indicate a diabetic's risk for developing long-term complications from diabetes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?